“And as you'll hear from David in a few minutes, we expect to grow our business this year.”

In context

“ertain non-GAAP financial measures to the most comparable GAAP measures are available at bms.com. And with that, I'll hand it over to Chris. Chris Boerner: Thanks, Tim, and good morning to all of you. I'm very pleased to be speaking to you on our earnings call for the first-time as a CEO, and I'm excited about the opportunity for our company to continue to deliver transformational medicines for patients. Please turn to Slide 4. Q4 2023 was a good quarter, including strong sales momentum in our inline and new product portfolio with 9% growth and nearly $10 billion in revenue with growth across multiple key brands, including Eliquis, Opdivo, Reblozyl, Opdualag, Breyanzi, Camzyos and Sotyktu. We also continued to generate significant cash flows from operations of $4.3 billion in the quarter. And as you'll hear from David in a few minutes, we expect to grow our business this year. During the fourth quarter, we also achieved important pipeline milestones and several key business development transactions to strengthen our growth profile. This is an important time for BMS. I know that many of you are focused on our strategy to navigate the decade and on the importance of disciplined execution at the company. We are writing the next chapter for BMS and with that comes an opportunity for change. So let me take a few minutes to tell you about our strategy to navigate our LOEs and be very clear about my focus on execution. Let's go to Slide 5 and how we see the company today. When we look at our business, it's comprised of two portfolios. First, we see a legacy portfolio of well-established products facing headwinds such as IRA. Though this portfolio is declining, it is e”